Dow Alzheimer’s Transforming Care Award

Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Care Award (TrCA) supports clinical research or clinical trials evaluating interventions, innovations, and solutions in critical areas for dementia care for individuals with Alzheimer’s disease and Alzheimer’s disease related dementia (AD/ADRD) and their care partner(s).

Distinctive Features:

Clinical research and clinical trials are allowed; however, clinical trials solely testing or evaluating pharmacological interventions do not meet the intent of this funding opportunity.Studies utilizing animal models do not meet the intent of the mechanism and are not allowed.Preliminary data are required.Community collaboration is required for research prospectively enrolling human subjects.The AZRP encourages studies to leverage existing cohorts/datasets. Cohorts consisting of individuals 65 years or younger are also encouraged.Career Initiation or Transition (CIT) Partnership Option: The TrCA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet the CIT Partnership Option eligibility requirements at the time of application submission.